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Moderate sodium restriction in hypertensive subjects: Renal effects of
ACE.inhibition. It has been suggested that All-mediated renal mecha-
nisms limit the efficacy of moderate sodium restriction in the lowering
of blood pressure (BP) in hypertension. We therefore studied renal
hemodynamics and sodium handling in nine essential hypertensives in
balance on 200 and on a 50 mmol sodium diet, before and during
ACE-inhibition (enalapril 10 mg bid for 8 days) in a cross-over fashion.
BP was similar on 50 and 200 mmol Na before enalapril, the fall in BP
during enalapril was significantly more pronounced on 50 mmol Na. On
50 mmol Na, GFR and filtered Na were significantly lower, and tubular
reabsorption was significantly higher than on 200 mmol Na. GFR
increased during enalapril in 50 but not on 200 mmol Na. Consequently,
the differences in GFR and filtered load elicited by sodium restriction
were no longer present during ACE-inhibition. In contrast, the differ-
ences in tubular reabsorption between 50 and 200 mmol Na persisted
during enalapril. In conclusion, moderate sodium restriction, not af-
fecting BP, can elicit a renal hemodynamic response. As this response
is blunted by ACE-inhibition it is probably mediated by All. This
blunting may contribute to the increased sodium sensitivity of BP
during ACE-inhibition. The adaptation of tubular sodium reabsorption
is not affected by ACE-inhibition.
The kidney plays a central role in the homeostatic response to
sodium restriction [I]. When sodium intake is reduced to very
low levels (<10 mmol Na daily), sodium excretion decreases
exponentially and excretion matches intake again after three to
five days [2]. The renal adaptation to this new state of sodium
balance is characterized by decreases in glomerular filtration
rate (GFR) and effective renal plasma flow (ERPF), and a
redistribution of renal blood flow [3, 4]. Studies in animals and
in man have provided ample evidence that the renin—angi-
otensin—aldosterone—system (RAAS) mediates this response
[5—7].
It has long been known that severe sodium restriction leads to
a fall in blood pressure [8]. In antihypertensive treatment
however, severe sodium restriction is impracticable and there-
fore, attention has been shifted to a more moderate restriction
of dietary sodium [9]. Unfortunately, moderate sodium restric-
tion lowers blood pressure only in a proportion of the patients
thus treated.
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It has been suggested that above—mentioned RAAS-mediated
renal adaptation limits the efficacy of sodium restriction in the
lowering of blood pressure [101. Yet the renal response to
moderate sodium restriction in hypertensive man is not well—
defined, and neither is the role of the RAAS in this response.
We therefore studied renal hemodynaniics and renal sodium
handling in patients with essential hypertension on a moder-
ately restricted and on a liberal sodium intake in a cross—over
fashion. To assess the importance of the RAAS in the renal
adaptive responses we repeated the studies after blocking the
system by one week of treatment with the angiotensin I
converting enzyme (ACE) inhibitor enalapril.
Methods
Patients
Nine patients, four male and five female, with uncomplicated
essential hypertension were studied. Diagnostic work—up in-
cluded rapid sequence urography in all patients, and renal
angiography if considered appropriate. Age ranged from 36 to
54 years (median 44). Renal function was normal, as assessed
by a GFR 90 mllmin/l.73 m2 at entry. There were no signs of
heart failure. Concomitant medication was not allowed. The
patients gave informed consent. The study was approved by the
ethical committee of the University Hospital.
Protocol
Previous medication had been withdrawn for at least four
weeks before the study. Two weeks before the study the
patients were instituted on a rigidly standardized diet, that is
either 50 or 200 mmol sodium daily with standardized potassium
(100 mmol) and fluid intake (2500 ml daily). Then the patients
were hospitalized. After a run—in period of at least a week when
blood pressure, sodium excretion and body weight were al-
lowed to stabilize, renal function studies were performed.
Thereafter enalapril (10mg bid) was given for eight days. Renal
function studies were repeated on the eighth day of treatment.
Subsequently the medication was withdrawn. Patients were
then crossed over to the other diet, and after a period of at least
two weeks the whole study was repeated.
During the run—in as well as during the treatment period,
24-hour urine was collected continuously for determination of
the excretion of sodium, potassium and creatinine. Cumulated
815
816 Navis et a!
Table 1. Baseline values (mean SEM)
8 0
Time, days
Fig. 1. Effects of enalapril on the urinary excretions of sodium and
potassium (upper panels) and on cumulated sodium- and potassium-
balance (lower panels). Data on low sodium intake are depicted by
continuous lines, data on liberal sodium by broken lines. Data are
presented as mean SEM.
sodium balance was calculated with the mean of the last three
control days as baseline value. Blood pressure was measured
four times daily with a non-invasive automatic device (Dma-
map') after 20 minutes of supine rest. The mean of these four
readings is given in Table 1. Blood samples for the determina-
tion of plasma renin activity (PRA) and plasma aldosterone
concentration (PAC) were drawn after 20 minutes of supine rest
and just before the morning dose of enalapril was given (8:00
a.m.). Body weight was measured daily (8:00 a.m.).
Treatment with enalapril resulted in an increase in sodium
excretion on both sodium intakes (Fig. 1). This increase was
already apparent on the first day of treatment in seven out of
nine, and in five out of nine patients on low and liberal sodium,
respectively. After one week of treatment sodium excretion
matched intake again in all patients. By then the net sodium loss
from the body was 105 22 and 124 18 mmol on low and
liberal sodium, respectively (Fig. 1). The sodium loss was not
significantly different for the different sodium intakes; for
individual patients the sodium loss was virtually similar on both
sodium intakes (r = 0.77, P < 0.01). The negative sodium
balance was accompanied by a fall in body weight on both
sodium intakes (Table 2). Potassium excretion tended to de-
crease somewhat with enalapril (Fig. I), but the decrease did
not reach statistical significance. Consequently, potassium bal-
ance did not change. The sum of the excretions of sodium and
potassium, as an index of distal sodium delivery, increased in
parallel with sodium excretion.
Methods
GFR and ERPF were measured simultaneously as the clear-
ance of 1251-iothalamate and 1311-Hippuran [11], respectively.
During the renal function studies the patients were in the supine
position. After a priming dose was given, the radiopharmaceu-
ticals were infused at a constant rate (Braun Unita II pump).
After an equilibration period of 1.5 hour two 2-hour clearances
were determined, each calculated from the 2-hour urinary
tracer excretions and the mean serum tracer values from three
samples drawn at the start, midway and the end of each
Sodium
200 mmol
Sodium
50 mmol % change P
MAP,mmHg 109±2 110±2 +1±2 NS
GFR, ml/min/1.73 m2 Ill 4 104 4 —7 2 <0.02
ERPF, ml/min/1.73 m2 431 22 415 27 —4 3 <0.1
FF 0.261 0.006 0.255 0.010 + I 3 NS
PRA, nmolA 1/i/hr 1.0 0.3 2.5 0.8 + 190 59 <0.01
PAC, nmol/liter 0.44 0.10 0.80 0.16 +94 19 <0.01
UNV, mmol/24 hr 201 14 45 7 —77 6 <0.01
UKV, mmol/24 hr 75 5 75 5 0 0 NS
Serum Na, mmol/liter 142 I 141 1 —1 I NS
K, mmol/liter 4.3 0.1 4.4 0.1 +4 4 NS
Body weight, kg 76.2 3.6 75.2 3.8 —1.4 1.1 NS
Table 2. Responses to enalapril (mean 5EM)
Sodium 200
mmol % change P
Sodium 50
mmol % change P
MAP 98 2 —10 1 <0.01 94 2 —15 I <0.01
GFR 112±4 +1±2 NS 110±4 +6±2 <0.02
ERPF 465 25 +8 2 <0.02 473 30 +15 4 <0.01
FF 0.243 0.010 —7 2 <0.02 0.236 0.010 —7 3 <0.02
PRA 6.5 1.8 +487 113 <0.01 14.3 5.4 -1-513 109 <0.01
PAC 0.40 0.09 —6 9 NS 0.77 0.18 —9 13 NS
UNaV 212±16 +2±5 NS 49±7 +4±5 NS
serum Na 140 I 0 1 NS 140 I 0 I NS
serum K 4.5 0.2 +5 2 NS 4.5 0.2 +2 3 NS
body weight 75.3 3.3 —1.1 0.2 <0.01 74.2 3.3 —1.1 0.7 <0.05
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two—hour period. The mean of the two clearances is given.
During the procedure a diuresis of at least 200 ml/2 hr was
maintained by oral administration of fluids. The coefficients of
variation of the day—to—day determinations are 2.2 for GFR and
5% for ERPF, respectively [11].
PRA and PAC were measured by radio—immunoassay [12,
13]. Serum and urinary electrolytes were measured by standard
auto-analyzer techniques.
Data are presented as mean SEM. Statistical evaluation was
performed according to the Wilcoxon test for paired data, each
patient being his own control. Results were considered statis-
tically significant at a 5% level.
Results
Mean values for blood pressure and renal hemodynamics as
well as hormonal parameters on both sodium intakes are given
in Table I. Blood pressure was similar on both sodium intakes.
GFR was significantly lower on the low sodium diet. In seven
out of nine patients ERPF also was lower on the sodium
restricted diet (Fig. 2). Both PRA and PAC were higher on
restricted sodium intake (Table 1).
Treatment with enalapril resulted in a fall in blood pressure
on both sodium intakes (Table 2); the fall in blood pressure was
more pronounced on the low sodium intake (P < 0.02).
The effects of enalapril on renal hemodynamics are shown in
Figure 3. GFR increased during enalapril on the low sodium diet
despite the fall in blood pressure. On liberal sodium intake
however, no change was observed. Enalapril induced an in-
crease in ERPF on both sodium intakes, the increase being
more pronounced on the low sodium intake (P < 0.02). No
relationship was found between the fall in mean arterial pres-
sure after enalapril and the responses of GFR (r = —0.27 and
—0.11 on low and liberal sodium, respectively) and ERPF (r =
—0.53 and —0.22 on low and liberal sodium, respectively).
Filtration fraction decreased similarly on both sodium intakes.
A sustained rise in PRA was observed after enalapril on
either diet (Fig. 4). PAC decreased in all patients at the onset of
treatment, with a gradual return to baseline values during the
next days of treatment. The renal response to enalapril was not
.. *
correlated with either the log of initial PRA (r = 0.18 and 0.25
for GFR and r = —0.45 and —0.38 for ERPF on low and liberal
sodium, respectively), or with the change in PRA on either diet
— ** —
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Fig. 2. The individual values of GFR and ERPF on liberal (200 mmol)
and low (50 mmol) sodium intake. * P < 0.02. 10
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Fig. 3. Effects of enalapril on GFR and ERPF on liberal (broken lines)
and on low (continuous lines) sodium intake. Data are given as absolute
values (upper panel) and as percentage change (lower panel). Mean
SEM. * P < 0.01.
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Fig. 4. Effects of enalapril on PRA (upper pane!) and PAC (lower
pane!), on low (continuous lines) and on liberal (broken lines) sodium
intake. Mean SEM.
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(r 0.11 and —0.09 for GFR and r = 0.17 and 0.23 for ERPF on
low and liberal sodium, respectively).
The parameters of renal sodium handling in steady state, both
with (measured at day 8; at that time sodium excretion matched
intake again) and without enalapril, are given in Figure 5. It
shows the urinary excretion of sodium, the total amount of
sodium filtered at the glomerulus, and, calculated from these
two, the percentage of sodium reabsorbed by the tubules.
Without enalapril, the lower sodium excretion on the 50
mmol sodium diet is due to both a fall in the filtered load of
sodium (P < 0.02) and a rise in net tubular reabsorption (P <
0.01). During enalapril however, the situation is quite different.
With enalapril the decrease in filtered load during sodium
restricted diet is no longer apparent and the fall in urinary
sodium excretion now only is accounted for by a rise in net
tubular reabsorption (P < 0.01).
Discussion
The purpose of our study was to document the renal response
to a moderate restriction of dietary sodium in essential hyper-
tension and to establish the role of the RAAS in this response.
We chose to study the 50 to 200 mmol range because 200 mmol
approximates the habitual intake in our region, and indeed in a
greater part of the western world, and 50 mmol is the sodium
intake we recommend to our hypertensive patients.
It has long been known that a dietary restriction of sodium to
less than 10 mmol/24 hr (that is, to less than 5% of the habitual
intake) results in a decrease in GFR and ERPF in hypertensive
patients [81 and in healthy individuals [3]. Our results show that
a moderate restriction to approximately 25% of the habitual
intake is already associated with a fall in GFR and, albeit less
consistently, ERPF.
We observed an increase in sodium excretion after enalapril
in all patients, resulting in a net sodium loss of approximately
100 mmol on either sodium intake. This amount of sodium is
equivalent to approximately 0.75 liter of extracellular fluid,
which is in accord with the weight loss we observed. The effects
of enalapril on renal hemodynamics and sodium handling were
studied after one week of treatment. At that time sodium
excretion matched intake again, thus the patients were in a new
sodium steady—state. Potassium excretion tended to decrease
somewhat, but the decrease did not reach statistical signifi-
cance.
The effects of enalapril on GFR and ERPF were significantly
more pronounced on low sodium intake. This underlines once
more the importance of sodium status when considering the
effects of ACE-inhibition. It could be that a large part of the
divergence in data dealing with the effects of ACE-inhibitors on
GFR is accounted for by differences in the sodium status. Our
findings are in accord with a variety of acute experiments in
animals [6, 7] and man [5, 14] in which salt—loading blunted or
abolished the increase in renal blood flow observed after
ACE-inhibition or after an All-antagonist. This has provided
evidence that the RAAS, probably All-mediated vasoconstric-
tion, is involved in the renal hemodynamic response to sodium
restriction [15]. Yet it has recently been called doubtful that the
renal hemodynamic response is only accounted for by the
RAAS in view of the quite pronounced changes in the renin—
system as compared to the subtle changes in renal function [16].
This is the first study, to our knowledge, with the individual
subjects as their own control, thus allowing a strict comparison
of the responses to ACE-inhibition on the different sodium
intakes. In our patients ACE-inhibition restored ERPF on the
low sodium diet to precisely the level measured on the liberal
sodium intake. Similarly, ACE-inhibition restored GFR on the
low sodium diet to a level only insignificantly below that on
liberal sodium. As a change in GFR is related to the change in
ERPF as well as the change in blood pressure [17], the less
precise match of GFR may be due to the somewhat more
pronounced fall in blood pressure on low sodium intake. Our
results are in good agreement with the abovementioned studies,
and again provide evidence that the lower values of GFR and
ERPF during low sodium intake are due to all All-mediated
renal vasoconstriction, although they do not rule out the
possibility of a role for other hormonal systems.
The adaptation of renal sodium handling to sodium restriction
was characterized by both a decrease in the amount of sodium
filtered (mainly due to a decrease in GFR) and an increase in
sodium reabsorbed (Fig. 5). This adaptation was altered by
treatment with enalapril. With enalapril the difference in filtered
load between low and liberal sodium was no longer apparent,
whereas the difference in tubular reabsorption between low and
liberal sodium intake was still present. This could mean that
ACE-inhibition blunts the adaptation of GFR (and consequently
the adaptation of filtered load) to altered sodium intake. This
also suggests that tubular adaptive mechanisms are not af-
fected, but our study design, only providing data on overall
sodium reabsorption, does not allow support of this hypothesis.
Sodium loss induced by enalapril
The net sodium loss we found is consistent with our earlier
findings with enalaprilic acid and with the findings of other
investigators [18, 19]. The sodium loss can be expected to have
influenced the absolute levels of both filtered load and tubular
reabsorption after enalapril on either diet. As the sodium loss
was similar on both diets however, the sodium loss is less likely
to be involved in the phenomenon of blunting of the adaptation
of filtered load to altered sodium intake.
Enalapril induced a sustained rise in PRA on both sodium
intakes. Somewhat in contrast, PAC returned to baseline after
an initial decrease on both sodium intakes. With regard to the
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Fig. 5. Twenty-four urinarv sodium excretion (left panel), amount of
sodium filtered (middle pane!) and percentage of sodium reabsorhed(right panel) on both sodium intakes, without (open bars) and with
(hatched bars) ena!april. * P < 0.02, ** P < 0.01.
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effect on PAC a few remarks should be made. First, the initial
decrease in PAC could well have played a role in the sodium
loss at the onset of treatment. Second, the return to baseline of
PAC could be due to the sodium loss itself (which would imply
that the axis sodium balance, renin—angiotensin—aldosterone is
still functioning to some degree, despite ACE-inhibition), to
subtle changes in potassium balance, or to non-All or potas-
sium—mediated mechanisms of aldosterone release, that is
ACTH. In this respect it is of interest that in our patients the
difference between both PRA and PAC on low and liberal
sodium persisted under ACE-inhibition. This could suggest that
this systemic (circulating) RAAS activity is still modified in
response to sodium restriction, despite ACE-inhibition. As we
did not measure All levels, however, this evidence remains
circumstantial.
Relevance of the blunted glomerular response to sodium
restriction under ACE-inhibition
It could be that it impairs the capacity to maintain sodium
homeostasis, as has been shown after captopril in rats subject to
a much more pronounced sodium restriction [20]. Perhaps due
to the less—severe sodium restriction in our patients, our study
does not support this assumption. It could also be that, in
interplay with the effects of ACE-inhibition on the systemic
vascular bed, the blunting of the glomerular adaptive mecha-
nisms contributes to the greater sodium sensitivity of blood
pressure under ACE-inhibition.
In conclusion, an only moderate restriction of dietary sodium
elicited a distinct response of renal hemodynamics in patients
with essential hypertension. Both the amount of sodium filtered
and tubular sodium handling appeared to be involved in the
adaptation to sodium restriction. Treatment with ACE-inhibitor
enalapril blunted the renal hemodynamic responses to sodium
restriction. Therefore, these are likely to be mediated by
angiotensin II.
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